How to Select a Suitable Non-Mouse Animal Model
Materials Required
/
Background
Selecting a suitable non-mouse animal model is a structured decision based on the research question, required anatomy or physiology, disease mechanism, endpoint feasibility, translational relevance, and ethical justification[1][2].
Non-mouse models are preferred when mice cannot reproduce key human-relevant features, such as organ size, surgical anatomy, cardiovascular physiology, neuroanatomy, immune features, pharmacology, toxicology, or long-term clinical procedures[3][4][5].
Candidate species may include rats, rabbits, guinea pigs, ferrets, zebrafish, pigs, sheep, goats, dogs, cats, horses, and non-human primates, but each species must be justified by its specific scientific advantage rather than convenience or tradition[1][2][6].
Unresolved questions include how to quantify translational superiority across species, how to balance increased biological relevance against higher ethical burden, and when human-derived systems or new approach methodologies should replace animal use[7][8].
MCE has not independently verified the accuracy of these methods. They are for reference only.
Project Analysis
• Begin by defining the exact reason for leaving the mouse system, such as need for larger anatomy, longer lifespan, closer pharmacology, complex behavior, surgical access, immune similarity, or disease features absent in mice[1][3][4].
• Next, create a candidate-species matrix comparing face validity, construct validity, predictive validity, assay availability, genetic tools, sample accessibility, husbandry requirements, cost, ethical burden, and feasibility of refinement[2][6][7].
• Then, exclude species for which validated endpoints, clinical pathology references, humane monitoring, or procedural expertise are inadequate, because poor model execution can reduce validity even when the species is biologically attractive[5][9].
• If evidence remains insufficient, run a pilot designed for feasibility, endpoint variance, and welfare assessment rather than efficacy confirmation[9].
• After selection, implement rigorous design with randomization, blinding, sample-size justification, prespecified endpoints, humane stopping rules, and ARRIVE-compliant reporting[9][11].
• Finally, validate major findings in human-relevant systems such as clinical specimens, organoids, ex vivo tissue, cross-species biomarkers, or pharmacokinetic/pharmacodynamic comparisons before making translational claims[4][8][10].
• Next, create a candidate-species matrix comparing face validity, construct validity, predictive validity, assay availability, genetic tools, sample accessibility, husbandry requirements, cost, ethical burden, and feasibility of refinement[2][6][7].
• Then, exclude species for which validated endpoints, clinical pathology references, humane monitoring, or procedural expertise are inadequate, because poor model execution can reduce validity even when the species is biologically attractive[5][9].
• If evidence remains insufficient, run a pilot designed for feasibility, endpoint variance, and welfare assessment rather than efficacy confirmation[9].
• After selection, implement rigorous design with randomization, blinding, sample-size justification, prespecified endpoints, humane stopping rules, and ARRIVE-compliant reporting[9][11].
• Finally, validate major findings in human-relevant systems such as clinical specimens, organoids, ex vivo tissue, cross-species biomarkers, or pharmacokinetic/pharmacodynamic comparisons before making translational claims[4][8][10].
Phased Objectives
Objective 1: Define why a mouse model is insufficient.
• Research approach: compare the planned phenotype, mechanism, intervention, and endpoint against known mouse limitations.• Experimental model: no animal is used at this stage; candidate non-mouse species are reviewed.
• Experimental groups: mouse model, non-mouse small-animal candidates, large-animal candidates, and non-animal alternatives.
• Key techniques: systematic literature review, phenotype mapping, anatomical comparison, pathway comparison, and 3Rs assessment.
• Detection indices: disease resemblance, mechanistic validity, endpoint feasibility, translational relevance, welfare burden, and availability of validated assays.
• Expected results: a justified reason to move beyond mice or a decision to avoid animal escalation.
• Interpretation: a non-mouse model is justified only when it answers a question that mice or alternatives cannot answer adequately[1][2][7][8].
Objective 2: Rank candidate non-mouse species.
• Research approach: use a scoring matrix to rank species by scientific fit and ethical burden.• Experimental model: candidate species such as rat, rabbit, pig, sheep, dog, ferret, zebrafish, or non-human primate.
• Experimental groups: candidate species compared by literature-derived evidence.
• Key techniques: comparative anatomy, clinical pathology review, genetic/pathway comparison, feasibility analysis, and welfare assessment.
• Detection indices: organ similarity, disease phenotype, drug-target conservation, assay availability, sample-volume feasibility, husbandry feasibility, and harm-benefit ratio.
• Expected results: one species should show the strongest balance of validity, feasibility, and refinement.
• Interpretation: the selected species should be the least sentient and lowest-burden model that can answer the primary question[3][5][6][7].
Objective 3: Pilot-test model feasibility and endpoint reliability.
• Research approach: perform a limited pilot only if published evidence is insufficient.• Experimental model: top-ranked non-mouse species.
• Experimental groups: healthy control, disease or procedure model, sham or vehicle control where relevant, and reference comparator if available.
• Key techniques: clinical observation, imaging, histology, blood chemistry, molecular assays, physiological measurements, and welfare scoring.
• Detection indices: phenotype penetrance, variability, mortality, procedural feasibility, assay sensitivity, sample quality, and welfare impact.
• Expected results: the model should produce measurable endpoints with acceptable variability and manageable welfare burden.
• Interpretation: a model with high anatomical relevance but unstable endpoints should not proceed to confirmatory testing[2][5][9].
Objective 4: Validate translational and clinical relevance.
• Research approach: compare the non-mouse model with human disease, human tissue, clinical biomarkers, or target-species data.• Experimental model: selected non-mouse species plus human samples, organoids, ex vivo tissue, or clinical datasets.
• Experimental groups: animal control, animal disease model, human control, and human disease comparator.
• Key techniques: biomarker analysis, transcriptomics, pathology comparison, pharmacokinetic/pharmacodynamic testing, and endpoint alignment.
• Detection indices: conserved biomarkers, shared pathology, target engagement, exposure-response relationship, and clinical endpoint similarity.
• Expected results: the selected model should reproduce the specific human-relevant feature that justified non-mouse use.
• Interpretation: strong cross-species alignment supports translational use; weak alignment limits the model to exploratory or mechanistic claims[4][5][10].
Critical Points
Objective 1
• Produce a transparent justification for whether a non-mouse model is scientifically necessary; if the mouse model or non-animal system can answer the question, escalation to a non-mouse species is not justified[7][8].Objective 2
• Identify the species with the best match to the biological question, rather than the species that is simply available or familiar[1][2].Objective 3
• Show that the selected model has measurable, reproducible, and humane endpoints; excessive variability, high attrition, or severe welfare burden should trigger model redesign or replacement[5][9][11].Objective 4
• Show that animal findings align with human or target-species disease mechanisms, pathology, biomarkers, or pharmacology; this supports translational relevance, whereas discordance limits interpretation[4][8][10].Troubleshooting
1: a non-mouse species may be selected because of tradition, availability, or local expertise rather than scientific fit.
Alternative: require a written model-selection matrix comparing candidate species against the primary research objective[1][2].2: large animals may improve anatomical or procedural relevance but increase cost, ethical burden, and regulatory complexity.
Alternative: use the least complex species that provides the required endpoint, and use large animals only after smaller models or alternatives are insufficient[7][8].3: species-specific clinical pathology and background lesions may confound interpretation.
Alternative: use species-specific reference intervals, veterinary pathology expertise, and matched controls[5].4: drug targets, metabolism, or toxicity pathways may differ across species.
Alternative: compare target sequence, pathway biology, pharmacokinetics, and pharmacodynamics before selecting the model[6][10].5: a model may reproduce anatomy but not disease mechanism.
Alternative: separate face validity from construct validity and restrict conclusions to the level of validity actually demonstrated[3][4].References:
- [1]. Veening-Griffioen DH, et al. Tradition, not science, is the basis of animal model selection in translational and applied research. ALTEX. 2021;38(1):49-62. [Content Brief]
- [2]. Mukherjee P, et al. Role of animal models in biomedical research: a review. Lab Anim Res. 2022;38(1):18. [Content Brief]
- [3]. Lossi L, et al. Anatomical features for an adequate choice of experimental animal model in biomedicine: II. Small laboratory rodents, rabbit, and pig. Ann Anat. 2016;204:11-28. [Content Brief]
- [4]. Azkona G, et al. Mice in translational neuroscience: What R we doing? Prog Neurobiol. 2022;217:102330. [Content Brief]
- [5]. Bau-Gaudreault L, et al. Research-relevant clinical pathology resources: emphasis on mice, rats, rabbits, dogs, minipigs, and non-human primates. ILAR J. 2021;62(1-2):76-90. [Content Brief]
- [6]. Bhoumik P, et al. Translational safety genetics. Toxicol Pathol. 2017;45(1):119-126. [Content Brief]
- [7]. Walker RL, et al. From mice to monkeys? Beyond orthodox approaches to the ethics of animal model choice. Animals (Basel). 2020;10(1):77.
- [8]. Kaplan BLF, Hoberman AM, Slikker W Jr, Smith MA, Corsini E, Knudsen T, et al. Protecting human and animal health: the road from animal models to new approach methods. Pharmacol Rev. 2024;76(2):251-266. [Content Brief]
- [9]. Percie du Sert N, Hurst V, Ahluwalia A, Alam S, Avey MT, Baker M, et al. The ARRIVE guidelines 2.0: updated guidelines for reporting animal research. PLoS Biol. 2020;18(7):e3000410. [Content Brief]
- [10]. Kamato D, et al. Non-mouse models of atherosclerosis: approaches to exploring the translational potential of new therapies. Int J Mol Sci. 2022;23(21):12964. [Content Brief]
- [11]. Landis SC, Amara SG, Asadullah K, Austin CP, Blumenstein R, Bradley EW, et al. A call for transparent reporting to optimize the predictive value of preclinical research. Nature. 2012;490(7419):187-191. [Content Brief]
LinkedIn
Researchgate
Instagram
X
Facebook
WhatsApp
Reddit
Mail